The takeover-focused Betaville blog sent an alert to its subscribers related to a rumor regarding Immunovant (IMVT), sources tell The Fly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant initiated with a Hold at Truist
- Immunovant price target lowered to $33 from $37 at JPMorgan
- 3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
- Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating
- Immunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating